Telix to acquire ITM in $1.65B radiopharma merger with up-to-$700M earn-out
TL;DR
Telix Pharmaceuticals will acquire ITM Isotope Technologies in a deal worth at least $1.65 billion, with the potential to pay up to $700 million more if ITM’s lead radiopharmaceutical meets regulatory and sales milestones, creating a larger radiopharma player to compete with Novartis in the growing field.
Topics:businessbiotech#biotech#earn-out#itm-isotope-technologies#merger#radiopharmaceuticals#telix-pharmaceuticals
- Radiopharma companies merge after one receives surprise FDA rejection STAT
- Analysts ‘extremely bullish’ as Telix beams into Novartis’ territory with $1.6B ITM acquisition Fierce Biotech
- TLX: US$1.65B acquisition creates a global radiopharmaceutical leader with major growth potential TradingView
- Telix’s US$1.65 Billion ITM Deal Adds 105.8 Million Shares as Stock Falls 3% TechStock²
- Australian Shares Flat; Telix Pharmaceuticals to Acquire German Radiopharmaceutical Biotechnology Company for Initial $1.65 Billion Payment Yahoo Finance Australia
Want the full story? Read the original reporting
Read on STAT